GO:1905524 negative regulation of protein autoubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905524 describes any process that stops, prevents or reduces the frequency, rate or extent of protein autoubiquitination, a self-directed ubiquitin transfer reaction.
• Autoubiquitination is a common feature of RING-type E3 ligases such as TRAF6, cIAP1, XIAP and Mdm2, and its negative regulation controls their abundance and signaling output.
• Negative regulation of autoubiquitination is achieved by deubiquitinases, by stabilization factors that block self-directed ubiquitin transfer, and by conformational or post-translational switches.
• Dysregulated autoubiquitination control is linked to inflammatory signaling, apoptosis, DNA damage responses and cancer, making this GO term relevant to immunology and oncology.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the main tools for dissecting causal roles of genes that regulate autoubiquitination.
• EDITGENE provides end-to-end cell model and screening services to study negative regulation of protein autoubiquitination in disease-relevant backgrounds.
Description
GO:1905524, negative regulation of protein autoubiquitination, is a biological process term that captures any mechanism which stops, prevents or reduces the frequency, rate or extent of protein autoubiquitination. Autoubiquitination is the self-directed attachment of ubiquitin to a protein, typically an E3 ubiquitin ligase, and it often serves as a regulatory or quality-control event that alters the stability or activity of the modified protein. Because autoubiquitination can trigger degradation, change conformation or modulate signaling, the processes that restrain it are central to cellular homeostasis.
negative regulation of protein autoubiquitination At A Glance
| GO ID | GO:1905524 |
|---|---|
| GO term | negative regulation of protein autoubiquitination |
| Ontology | biological_process |
| Synonym | inhibition of protein self-ubiquitination; down-regulation of protein auto-ubiquitination; negative regulation of protein autoubiquitinylation |
| Major function | Restrains self-directed ubiquitin transfer on E3 ligases and other autoubiquitinating proteins, thereby controlling their stability, activity and downstream signaling |
| Related process | protein autoubiquitination (GO:0051865); protein ubiquitination; ubiquitin-dependent protein catabolic process |
| Cellular context | Cytoplasm, nucleus and signaling complexes where RING-type E3 ligases such as TRAF6, cIAP1, XIAP and Mdm2 operate |
| Disease relevance | Inflammation, innate immunity, apoptosis, DNA damage response and cancer |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, proteomics, ubiquitination assays and imaging |
What Is GO:1905524?
In your own words, GO:1905524 refers to any cellular process that negatively regulates protein autoubiquitination, meaning it reduces the frequency, rate or extent of the self-directed ubiquitin transfer reaction. This can occur through deubiquitinase activity, through stabilization of the E3 ligase, through conformational changes that prevent self-directed ubiquitin transfer, or through post-translational modifications that block the reaction.
Why Is negative regulation of protein autoubiquitination Important in Cell Biology?
Negative regulation of protein autoubiquitination is important because autoubiquitination directly controls the abundance and activity of E3 ligases and other signaling proteins, and its dysregulation can amplify or suppress immune, apoptotic and oncogenic pathways. Understanding this process helps researchers interpret how cells maintain signaling thresholds and how disease-associated mutations perturb them.
• Controls the stability and activity of RING-type E3 ligases such as TRAF6, cIAP1, XIAP and Mdm2.
• Shapes innate immune and inflammatory signaling by restraining TRAF6 autoubiquitination.
• Modulates apoptosis and cell survival through XIAP and cIAP1 regulation.
• Influences p53 responses via Mdm2 stability control.
• Provides a mechanism for deubiquitinases such as USP7 to stabilize substrates and affect tumorigenesis.
• Is relevant to sepsis-induced lung inflammation and antiviral immunity.
• Offers therapeutic hypotheses in cancer, inflammation and proteostasis disorders.
• Requires precise CRISPR models to distinguish causal effects from correlative changes.
What Happens During negative regulation of protein autoubiquitination?
Recognition of the autoubiquitination-prone E3 ligase
In simple terms: First, the cell must identify the protein that is ubiquitinating itself.
Negative regulation of autoubiquitination begins with recognition of an E3 ligase or other protein that is capable of self-directed ubiquitin transfer. TRAF6, cIAP1, XIAP and Mdm2 are examples of proteins whose autoubiquitination is subject to negative regulation. In each case, the regulatory process must engage the same protein that would otherwise ubiquitinate itself, often within a signaling complex.
Blocking or reversing self-directed ubiquitin transfer
In simple terms: The cell uses factors that stop the protein from tagging itself with ubiquitin.
Once the autoubiquitination-prone protein is engaged, negative regulation can occur by blocking the catalytic step or by removing ubiquitin that has already been attached. Deubiquitinases such as USP7 can reverse ubiquitin attachment and thereby perturb proteostasis. Stabilization factors can also prevent self-directed ubiquitin transfer, as shown for NEDD4-1 regulation of Mdm2 stability. In cIAP1, antagonist-induced conformational changes promote autoubiquitination, indicating that the opposite conformational state restrains it.
Conformational and post-translational control
In simple terms: Shape changes and chemical tags on the protein can switch autoubiquitination off.
Conformational changes are a major mechanism of negative regulation. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination, so the non-induced conformation is associated with reduced autoubiquitination. Post-translational modifications such as phosphorylation can stabilize XIAP and thereby limit its autoubiquitination-dependent turnover. These examples show that negative regulation is often a switch rather than a simple absence of activity.
Downstream consequences for stability and signaling
In simple terms: When autoubiquitination is blocked, the protein survives longer and signals differently.
Reduced autoubiquitination typically increases the stability or alters the activity of the target protein, which changes downstream signaling. Negative regulation of TRAF6 autoubiquitination limits sepsis-induced lung inflammation and innate immune responses. Stabilization of Mdm2 by NEDD4-1 regulation affects the p53 response. USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer, linking negative regulation of autoubiquitination to disease.
Integration with the ubiquitin-proteasome system
In simple terms: This process is part of the broader ubiquitin system that decides protein lifetimes.
Negative regulation of autoubiquitination is embedded in the ubiquitin-proteasome system. SCF E3-mediated autoubiquitination negatively regulates Cdc34 E2 activity, showing that autoubiquitination and its negative regulation can tune the catalytic cycle itself. Because autoubiquitination can target proteins for degradation, its negative regulation directly influences protein half-life and the composition of signaling complexes.
Key Genes Involved in GO:1905524 negative regulation of protein autoubiquitination
The following genes and proteins are experimentally implicated in negative regulation of protein autoubiquitination or in the autoubiquitination events it controls.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRAF6 | RING-type E3 ligase whose autoubiquitination is negatively regulated during inflammation | Sepsis-induced lung inflammation and innate immunity |
| SUFU | Regulates phase separation of TRAF6 and limits sepsis-induced lung inflammation | Inflammation and TRAF6 autoubiquitination control |
| NEDD4-1 | E3 ligase that regulates Mdm2 protein stability | p53 response and Mdm2 autoubiquitination |
| MDM2 | E3 ligase whose stability is controlled by NEDD4-1 | p53 pathway and cancer |
| XIAP | E3 ligase stabilized by Akt phosphorylation | Apoptosis and cell survival |
| CIAP1 | RING-type E3 ligase that undergoes antagonist-induced autoubiquitination | Apoptosis and NF-kB signaling |
| CDC34 | E2 enzyme whose activity is negatively regulated by SCF-mediated autoubiquitination | Cell cycle and ubiquitin conjugation |
| USP7 | Deubiquitinase that can reverse ubiquitination and affect proteostasis | Triple-negative breast cancer and tumorigenesis |
| CALPAIN2A | Protease that targets TRAF6 and limits innate immunity | Antiviral innate immunity |
| PRMT2 | Arginine methyltransferase that targets traf6 and attenuates antiviral immunity | Antiviral innate immunity |
| AKT | Kinase that phosphorylates and stabilizes XIAP | Apoptosis and survival signaling |
| SCF complex | E3 complex that mediates autoubiquitination of Cdc34 | Cell cycle and E2 regulation |
| TRAF6 signaling complex | Platform for TRAF6 autoubiquitination and its negative regulation | Inflammation and immunity |
| cIAP1 antagonist complex | Conformational switch controlling cIAP1 autoubiquitination | Apoptosis and NF-kB signaling |
| Mdm2-p53 axis | Regulatory node where Mdm2 stability controls p53 | DNA damage response and cancer |
| USP7 substrate network | Deubiquitination-dependent stabilization of proteins | Proteostasis and cancer |
How Is negative regulation of protein autoubiquitination Regulated?
Negative regulation of protein autoubiquitination is itself regulated at multiple levels. Conformational changes can switch autoubiquitination on or off, as shown for cIAP1 where antagonists induce a conformational change that promotes autoubiquitination. Post-translational modification, such as Akt-mediated phosphorylation of XIAP, can stabilize the protein and thereby limit its autoubiquitination-dependent turnover. Deubiquitinases such as USP7 provide a reversible layer of control by removing ubiquitin and perturbing proteostasis. In addition, E3 ligase complexes such as SCF can mediate autoubiquitination of E2 enzymes like Cdc34, which negatively regulates E2 activity and tunes the catalytic cycle. Together, these mechanisms allow cells to adjust autoubiquitination rates in response to signaling inputs.
negative regulation of protein autoubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRAF6 | Sepsis-induced lung inflammation and innate immunity | Knockout and tagged knock-in in macrophage or lung epithelial lines |
| MDM2 | p53 response and cancer | Point mutation and knockout in cancer cell lines |
| XIAP | Apoptosis and survival signaling | Overexpression and point mutation in cancer cell lines |
| CIAP1 | Apoptosis and NF-kB signaling | Knockout and overexpression in cancer cell lines |
| USP7 | Triple-negative breast cancer and proteostasis | Knockout and overexpression in breast cancer models |
Inflammation and sepsis
Negative regulation of TRAF6 autoubiquitination is directly linked to inflammatory disease. Sufu limits sepsis-induced lung inflammation by regulating phase separation of TRAF6, and calpain2a and prmt2 attenuate innate immunity by targeting TRAF6. These findings place GO:1905524 at the center of mechanisms that restrain excessive inflammatory signaling.
Cancer and p53 signaling
The Mdm2-p53 axis depends on controlled Mdm2 stability, and NEDD4-1 regulates Mdm2 protein stability and the p53 response. USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer, showing that deubiquitinase-dependent negative regulation of autoubiquitination has oncogenic relevance. XIAP stabilization by Akt phosphorylation further links autoubiquitination control to survival signaling in cancer.
Apoptosis and cell survival
cIAP1 and XIAP are E3 ligases whose autoubiquitination and stability influence apoptosis. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination, while Akt phosphorylation stabilizes XIAP. Negative regulation of autoubiquitination therefore contributes to the balance between cell death and survival.
Innate antiviral immunity
TRAF6 autoubiquitination is a key node in antiviral innate immunity. Zebrafish prmt2 attenuates antiviral innate immunity by targeting traf6, and calpain2a limits innate immunity by targeting TRAF6 in teleost fish. These studies show that negative regulation of TRAF6 autoubiquitination shapes host defense.
From negative regulation of protein autoubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for negative regulation of autoubiquitination? | CRISPR knockout cell line |
| Does a specific residue control autoubiquitination? | Point mutation knock-in cell line |
| Does a disease-associated variant alter autoubiquitination? | Knock-in of the variant in an isogenic background |
| Where and when does the protein interact with its regulator? | Tagged knock-in for imaging and immunoprecipitation |
| Does overexpression phenocopy loss of negative regulation? | Overexpression cell line |
| Which pathways depend on the regulator? | CRISPR library screening and bioinformatics |
How to Study the negative regulation of protein autoubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro ubiquitination assay | Self-directed ubiquitin transfer on a purified protein | Confirming autoubiquitination and its inhibition |
| Cell-based ubiquitination assay | Ubiquitin conjugates on target proteins in cells | Testing regulators of TRAF6, Mdm2 or XIAP |
| Mass spectrometry proteomics | Ubiquitination sites and protein abundance changes | Mapping downstream effects of altered autoubiquitination |
| Co-immunoprecipitation | Physical interactions between E3 ligases and regulators | Identifying stabilizing or blocking factors |
| Fluorescence imaging | Localization and condensation of signaling proteins | Studying TRAF6 phase separation and Sufu regulation |
| CRISPR knockout screening | Genes required for a phenotype | Discovering negative regulators of autoubiquitination |
| Bioinformatics pathway analysis | Enriched pathways among screen hits | Linking regulators to immune or cancer networks |
| Deubiquitinase inhibition assay | Reversal versus prevention of ubiquitination | Distinguishing USP7-like activity from blocking factors |
Ubiquitination and autoubiquitination assays
Direct measurement of autoubiquitination uses in vitro ubiquitination reactions and cell-based assays that detect ubiquitin conjugates on the target protein. These assays are essential to confirm that a candidate regulator changes the frequency or extent of self-directed ubiquitin transfer. They can be combined with deubiquitinase inhibitors to distinguish removal from prevention of ubiquitin attachment.
Proteomics and interactomics
Mass spectrometry-based proteomics can map ubiquitination sites and identify interaction partners of E3 ligases such as TRAF6, Mdm2 and XIAP. Quantitative proteomics after CRISPR perturbation reveals downstream changes in protein stability that result from altered autoubiquitination.
Imaging and phase separation analysis
Fluorescence imaging and phase separation assays can visualize how regulators such as Sufu control TRAF6 condensation and signaling. Tagged knock-in models allow tracking of the protein in live cells and correlation of localization with autoubiquitination status.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens combined with bioinformatics can identify genes that negatively regulate autoubiquitination in a given cell type or stimulus. Pathway enrichment of screen hits helps place candidate regulators within immune, apoptotic or proteostatic networks.
How CRISPR Can Be Used to Study GO:1905524 negative regulation of protein autoubiquitination
Knockout
CRISPR knockout of candidate genes is used to test whether a factor is required for negative regulation of autoubiquitination. Knockout of TRAF6 regulators such as Sufu, calpain2a or prmt2 alters inflammatory and antiviral signaling, providing causal evidence for their roles. Knockout of NEDD4-1 changes Mdm2 stability and the p53 response.
Point Mutation
Point mutation models allow precise testing of residues that control autoubiquitination or its negative regulation. For example, mutations that alter the conformational switch in cIAP1 or the phosphorylation site in XIAP can be introduced to test their effects on autoubiquitination. Such models separate catalytic activity from regulatory modification.
Knock-in
Knock-in of tags or disease-associated variants enables tracking and functional analysis of autoubiquitination regulators in an isogenic background. Tagged knock-in of TRAF6 or its regulators supports imaging of phase separation and interaction dynamics. Variant knock-in can reveal how patient mutations affect Mdm2 or USP7-dependent processes.
Overexpression
Overexpression models test whether increased levels of a regulator are sufficient to reduce autoubiquitination and change downstream signaling. Overexpression of XIAP or USP7 can stabilize survival or proteostasis pathways and phenocopy loss of negative regulation. These models complement knockout studies by testing sufficiency rather than necessity.
How EDITGENE Supports negative regulation of protein autoubiquitination Research
Researchers studying negative regulation of protein autoubiquitination-related genes often need to determine whether a candidate gene is causally involved in controlling autoubiquitination or is merely correlated with a signaling change. EDITGENE provides the cell models and screening services needed to move from correlation to causation in disease-relevant backgrounds.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of protein autoubiquitination research.
Frequently Asked Questions About negative regulation of protein autoubiquitination
What is GO:1905524 negative regulation of protein autoubiquitination?
GO:1905524 is a biological process term describing any process that stops, prevents or reduces the frequency, rate or extent of protein autoubiquitination, the self-directed attachment of ubiquitin to a protein.
What genes are involved in negative regulation of protein autoubiquitination?
Genes and proteins implicated include TRAF6, SUFU, NEDD4-1, MDM2, XIAP, CIAP1, CDC34, USP7, calpain2a, prmt2 and Akt.
Why is negative regulation of protein autoubiquitination important?
It controls the stability and activity of E3 ligases and signaling proteins, thereby shaping inflammation, apoptosis, p53 responses and cancer.
How is protein autoubiquitination negatively regulated?
Mechanisms include deubiquitinase activity, stabilization factors, conformational changes and post-translational modifications that block self-directed ubiquitin transfer.
Which diseases are linked to defects in negative regulation of autoubiquitination?
Sepsis-induced lung inflammation, antiviral immunity defects, cancer including triple-negative breast cancer, and apoptosis-related disorders have been linked to this process.
What experimental models are used to study GO:1905524?
CRISPR knockout, point mutation, knock-in, tagged knock-in and overexpression cell models, combined with ubiquitination assays, proteomics and imaging, are commonly used.
How does TRAF6 autoubiquitination relate to inflammation?
Negative regulation of TRAF6 autoubiquitination limits sepsis-induced lung inflammation and innate immune responses, as shown by studies of Sufu, calpain2a and prmt2.
What role does USP7 play in autoubiquitination regulation?
USP7 is a deubiquitinase whose inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer, linking it to negative regulation of ubiquitination.
Can CRISPR screens identify regulators of autoubiquitination?
Yes, CRISPR knockout screens combined with bioinformatics can identify genes required for negative regulation of autoubiquitination in specific cell types and stimuli.
What services does EDITGENE offer for studying GO:1905524?
EDITGENE offers knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening and bioinformatics services for autoubiquitination research.
Conclusion
GO:1905524 negative regulation of protein autoubiquitination is a focused biological process term that captures how cells restrain self-directed ubiquitin transfer on E3 ligases and other proteins. Experimental evidence from TRAF6, Mdm2, XIAP, cIAP1, Cdc34 and USP7 studies shows that this regulation is central to inflammation, apoptosis, p53 signaling and cancer. CRISPR-based cell models and screening approaches provide the causal tools needed to dissect these mechanisms and to identify therapeutic opportunities.
References
- 1. Li Y et al.. 2023. Sufu limits sepsis-induced lung inflammation via regulating phase separation of TRAF6.. Theranostics 13(11):3761-3780 PMID: 37441604
- 2. Xu C et al.. 2015. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.. Oncogene 34(3):281-9 PMID: 24413081
- 3. Dueber EC et al.. 2011. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination.. Science 334(6054):376-80 PMID: 22021857
- 4. Chen Y et al.. 2023. The protease calpain2a limits innate immunity by targeting TRAF6 in teleost fish.. Commun Biol 6(1):355 PMID: 37002312
- 5. Zhu J et al.. 2021. Zebrafish prmt2 Attenuates Antiviral Innate Immunity by Targeting traf6.. J Immunol 207(10):2570-2580 PMID: 34654690
- 6. Scaglione KM et al.. 2007. SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo.. Mol Cell Biol 27(16):5860-70 PMID: 17562869
- 7. Dan HC et al.. 2004. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).. J Biol Chem 279(7):5405-12 PMID: 14645242
- 8. Kim A et al.. 2026. USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer.. NPJ Breast Cancer 12(1) PMID: 42177192
